Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.

Our business ambition is to be the world’s leading and most valued generics company.

Our global portfolio comprises approximately 1 000 molecules, covering a wide range of therapeutic areas, which accounted for 2022 sales of USD 9.2 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.

Our products reach approximately 500 million patients every year. Our broad portfolio is spearheaded by our global leadership positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems. We also run a variety of targeted corporate responsibility programs.